Concepts (65)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lysine | 1 | 2024 | 74 | 0.900 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2024 | 102 | 0.880 |
Why?
|
| Dendrimers | 3 | 2019 | 15 | 0.850 |
Why?
|
| Drug Delivery Systems | 4 | 2020 | 225 | 0.750 |
Why?
|
| Gene Silencing | 1 | 2017 | 65 | 0.530 |
Why?
|
| Nanoparticles | 5 | 2020 | 288 | 0.520 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 198 | 0.490 |
Why?
|
| Neoplasms | 3 | 2021 | 818 | 0.270 |
Why?
|
| Biological Transport | 2 | 2024 | 120 | 0.260 |
Why?
|
| Acetylation | 1 | 2024 | 37 | 0.230 |
Why?
|
| HEK293 Cells | 1 | 2024 | 187 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 678 | 0.220 |
Why?
|
| Phosphorylation | 1 | 2024 | 575 | 0.210 |
Why?
|
| Albumins | 2 | 2019 | 12 | 0.200 |
Why?
|
| Nanomedicine | 2 | 2020 | 62 | 0.200 |
Why?
|
| Permeability | 2 | 2019 | 61 | 0.190 |
Why?
|
| Podocytes | 1 | 2021 | 11 | 0.180 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 21 | 0.180 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 4 | 0.180 |
Why?
|
| Drug Resistance, Multiple | 1 | 2020 | 20 | 0.170 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2019 | 1 | 0.160 |
Why?
|
| Parkinson Disease | 1 | 2019 | 46 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 167 | 0.160 |
Why?
|
| Humans | 10 | 2024 | 28121 | 0.150 |
Why?
|
| Exosomes | 1 | 2020 | 91 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 215 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2018 | 77 | 0.150 |
Why?
|
| Nanotubes, Carbon | 1 | 2018 | 50 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2018 | 105 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2021 | 295 | 0.140 |
Why?
|
| Eye Diseases | 1 | 2017 | 31 | 0.140 |
Why?
|
| Skin | 1 | 2018 | 148 | 0.130 |
Why?
|
| Nanostructures | 1 | 2017 | 63 | 0.130 |
Why?
|
| Stroke | 1 | 2019 | 252 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 301 | 0.120 |
Why?
|
| Animals | 7 | 2021 | 10399 | 0.110 |
Why?
|
| Inflammation | 1 | 2017 | 626 | 0.100 |
Why?
|
| Nanotechnology | 2 | 2020 | 68 | 0.080 |
Why?
|
| Blood-Brain Barrier | 2 | 2019 | 83 | 0.080 |
Why?
|
| Drug Carriers | 2 | 2019 | 115 | 0.070 |
Why?
|
| Apoptosis | 2 | 2021 | 771 | 0.060 |
Why?
|
| Streptozocin | 1 | 2021 | 11 | 0.050 |
Why?
|
| Drug Approval | 1 | 2021 | 10 | 0.050 |
Why?
|
| Nucleic Acids | 1 | 2020 | 10 | 0.040 |
Why?
|
| Mice | 2 | 2021 | 4645 | 0.040 |
Why?
|
| Nootropic Agents | 1 | 2019 | 4 | 0.040 |
Why?
|
| PC12 Cells | 1 | 2019 | 21 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cations | 1 | 2018 | 11 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 276 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 32 | 0.040 |
Why?
|
| Skin Absorption | 1 | 2018 | 2 | 0.040 |
Why?
|
| Particle Size | 1 | 2018 | 101 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2018 | 29 | 0.040 |
Why?
|
| Proteins | 1 | 2020 | 251 | 0.040 |
Why?
|
| RNA Interference | 1 | 2018 | 137 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2017 | 8 | 0.040 |
Why?
|
| Polymers | 1 | 2018 | 117 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 968 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 755 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 694 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2017 | 97 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 1570 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 1564 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1324 | 0.030 |
Why?
|